|
| You BETer be aware – learnings from a negative Phase 1 study |
|
https://doi.org/10.18632/oncotarget.26898
|
| 3145-3146 |
|
| Target HER four in breast cancer |
|
https://doi.org/10.18632/oncotarget.26867
|
| 3147-3150 |
|
| PRMT5 prognostic value in cancer |
|
https://doi.org/10.18632/oncotarget.26883
|
| 3151-3153 |
|
| Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation |
|
https://doi.org/10.18632/oncotarget.26872
Deborah Backs, Ilknur Saglam, Claudia Löffler, Sandra Ihne, Caroline Morbach, Susanne Brenner, Christiane Angermann, Georg Ertl, Stefan Frantz, Stefan Störk, Stefan Knop, Gülmisal Güder
|
| 3154-3165 |
|
| Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma |
|
https://doi.org/10.18632/oncotarget.26899
Jun Qin, Irfan Shaukat, Didier Mainard, Patrick Netter, Lydia Barré, Mohamed Ouzzine
|
| 3166-3182 |
|
| Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma |
|
https://doi.org/10.18632/oncotarget.26900
Zuolin Ying, Lisa Shiue, Katherine Park, Jutta Kollet, Pedram Bijani, Meghali Goswami, Madeleine Duvic, Xiao Ni
|
| 3183-3197 |
|
| Bazedoxifene as a novel strategy for treatment of pancreatic and gastric adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.26833
Claudia Burkhardt, Leo Bühler, Matthieu Tihy, Philippe Morel, Michel Forni
|
| 3198-3202 |
|
| Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides |
|
https://doi.org/10.18632/oncotarget.26921
|
| 3203-3206 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß